Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma.

Trial Profile

Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cyclophosphamide; Dexamethasone; Idarubicin; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2010 Planned end date changed from 1 Dec 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Lead trial investigator (Schmidt-Wolf I) identified as reported by ClinicalTrials.gov.
    • 17 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top